DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/6zhbzj/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Ache Laboratorios Farmaceuticos S/A
- advanceCor GmbH
- AFFiRiS AG
- Arisaph Pharmaceuticals, Inc.
- Artery Therapeutics, Inc.
- AstraZeneca Plc
- Athera Biotechnologies AB
- AtheroNova Inc.
- AuraSense Therapeutics, LLC
- Bayer AG
- Bridge Bioresearch Plc
- Campus Technologies Freiburg GmbH
- Cardax Pharmaceuticals, Inc.
- ChemoCentryx, Inc.
- CohBar Inc.
- DoNatur GmbH
- Dr. Reddy's Laboratories Limited
- Dybly AG
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GenKyoTex S.A.
- Gilead Sciences, Inc.
- Isis Pharmaceuticals, Inc.
- Jenrin Discovery, Inc.
- Johnson & Johnson
- KineMed, Inc.
- Kowa Company, Ltd.
- Lead Discovery Center GmbH
- MedImmune, LLC
- Merck & Co., Inc.
- MI.TO. Technology S.r.L.
- Novartis AG
- Omeros Corporation
- OPKO Health, Inc.
-
Otsuka Holdings Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/6zhbzj/atherosclerosis
